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Abstract 
Liposomal formulations composed of phospholipids with different unsaturation degrees, head 
groups and at different cholesterol content have been tested for the encapsulation of Peptide Nucleic 
Acid (PNA) oligomers. The best loading capability (177 μg, ER% = 87.2) was obtained for pure 
liposomes of phosphatidylglycerol (DOPG) with negatively charged head group. The insertion of a 
10-20% of cholesterol in DOPG based liposomes provides a slight decrease (~160 μg) of the PNA 
loading. On the other hand, the cholesterol addition (20-30%) slows down the PNA’s release (~ 
27%) in fetal bovine serum from the liposomal formulation. Based on the encapsulation and the 
release properties, PEGylated DOPG liposomes with a percentage of cholesterol of 10-20% are the 
optimal formulation for the loading of PNA-a210.  
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1. Introduction 
 
Oligonucleotide based molecules represent a potent tool to unravel and modulate the expression and 
the function of genes. In this context the application of oligonucleotide analogues, such as Peptide 
Nucleic Acids (PNAs), showing resistance to degradation in vivo, high affinity and specificity of 
binding toward complementary DNA and RNA, is widespread (1-3). Peptide Nucleic Acids, 
containing a pseudo-peptide backbone in place of the sugar-phosphate backbone, have been tested 
as antisense, antigene molecules and recently as inhibitors of the function of miRNAs (4-7). The 
limited efficiency of transfection of Peptide Nucleic Acids in cells severely hampers their 
application in vivo. In the last few years the challenge has been tackled in many different ways(8). 
A recently proposed strategy entails the conjugation of PNAs to polyanionic molecules, such as 
polyaspartic acid peptides, followed by the packing with polycations, including polyethylenimine 
(PEI) and lipofectamine (5). Extension of a PNA sequence by a 6-mer PNA polyA allows its 
delivery upon hybridization to a polythymidilic acid containing both N,N-dimethylaminopropyl and 
octyl thiophosphate triester elements (9). Alternatively, PNAs have been hybridized to DNA and 
immobilized on cationic nanoparticles (10). PNAs have been also conjugated to a variety of 
carriers, including peptides, PEI, cholic acid, cholesterol (7; 11-13). A very laborious approach 
consists in the modification of the PNA backbone by insertion of positively or negatively charged 
pendant groups at the alpha or gamma position (14-16). In few cases naked PNAs have been 
delivered to cells: biodegradable poly(lactic-co-glycolic acid) (PLGA) nanoparticles have been used 
to deliver a triplex forming PNA to CD34 cells (17). Nanoparticles based on PLGA/ polyaminobeta 
ester derivatized on the surface with the MPG peptide were demonstrated to deliver mixtures of 
PNA and DNA to CF mouse model and to cause correction on the CFTR gene. Recently, we have 
reported the delivery of a PNA oligomer (PNA-a210) to K562 cells by a liposomal formulation 
based on egg phosphatidylcholine/ cholesterol/ 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-
N-[carbonyl-methoxy(polyethylene glycol)2000 (egg PC/CHO/DSPE-PEG2000 at 47/47/6 molar 
ratio) and we have demonstrated that this formulation triggers low or no toxicity to cells (18). The 
PNA oligomer targets the noncoding RNA miRNA-210, which is involved in the regulation of 
raptor and -globin genes and in the erythroid differentiation of leukemic K562 cells(19). Effective 
downregulation of the miR-210 was observed upon treatment of K562 cells with the liposome 
encapsulated PNA-a210. Similar formulations, SPC/CHO/DSPE-PEG2000 (47/47/6 molar ratio) 
and HSPC/CHO/DSPE-PEG2000 (56/39/5) have been reported for the encapsulation of peptides 
and for the liposomal drug Doxil (20). Replacement of SPC or HSPC by egg PC, which has a 
higher degree of saturated chains, is expected to improve the stability of the liposomes, essential for 
the in vivo application of liposomal drugs. Goal of this work is to obtain a liposomal formulation 
with a higher PNA loading ability, as compared to the previously reported one (18). The toxicity 
effects, likely due to lipids, will therefore be further reduced. To this aim, we tested a number of 
liposomal formulations, prepared using phospholipids containing two alkyl chains at eighteen 
carbon atoms (see Fig. 1). The effects of the unsaturation of the hydrophobic portion, of the head 
group and of the percentage of the cholesterol were evaluated in terms of structural features, PNA 
loading and release capabilities of the liposomes.  
 
2. Materials and methods 
 
Egg Phosphatidylcholine (Egg PC) 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-
dioleoyl-sn-glycero-3-phosphocholine (DOPG), L-α-phosphatidylcholine hydrogenated soy 
(HSPC), cholesterol (CHO) and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[carbonyl-
methoxy(polyethylene glycol)2000] (ammonium salt) (DSPE-PEG2000) were purchased from 
Avanti Polar Lipids (Alabaster, AL). Dialysis tubing 8-10 kDa MWCO was purchased by Pierce 
Protein (USA). The PNA-a210 was prepared as described elsewhere (18). The sequence of PNA-
a210 follows: H-ccgctgtcacacgcacag-NH2. 
 
2.1 Liposome preparation and PNA loading 
A stock solution of PNA-a210 was prepared in 10 mM phosphate buffer at pH 7.4, containing the 
0.2% wt glycerol. Concentration was determined by UV-Vis measurements, carried out on a 
Thermo Fisher Scientific Inc (Wilmington, Delaware USA) Nanodrop 2000c spectrophotometer 
equipped with a 1.0 cm quartz cuvette (Hellma) using a molar absorptivity (ε) of 172400 M-1 cm-1 
at λ = 260 nm. All liposomal formulations, reported in Table 1, were prepared combining the thin 
film/sonication and the freeze/thawing methods. Briefly, the required amounts of phospholipids and 
cholesterol were dissolved in 3 mL of chloroform and the organic solvent was removed under a 
stream of N2 to obtain a homogeneous film on the wall of the vial. Any trace solvent was further 
removed keeping the vial under vacuum for 15 minutes. Each dry lipid film was hydrated in 1.0 mL 
of 10 mM phosphate buffer and sonicated for 10 minutes. The total lipid concentration was 15 mM. 
Then, 500 μL of the PNA-a210 stock solution (1.0 mg/mL) were added to the preformed liposomes; 
the resulting mixture was frozen/thawed by dipping the glass tube for 1 minute into a dry ice bath 
for rapid cooling and then transferred into a bath at 65 °C, allowing each sample to thaw out for 4 
min, and finally vortexed for another minute. Five cycles were performed to promote the entry of 
PNAs into the liposomes. The liposomal suspension was extruded 10 times, using a thermobarrel 
extruder system (Northern Lipids Inc, Vancouver, BC, Canada) under nitrogen through a 
polycarbonate membrane (Nucleopore Track Membrane 25 mm, Whatman, Brentford, UK) with 
0.1 μm pore size. Extrusion was performed at different temperatures: 65°C for HSPC based 
liposomes (HSPC-94, HSPC-84, HSPC-74, HSPC-64 and HSPC-47), 25°C for all DOPC and 
DOPG liposomes (DOPC-94, DOPC-84, DOPC-74, DOPC-64, DOPC-47, DOPG-94, DOPG-84, 
DOPG-74, DOPG-64 and DOPG-47) and for two PC formulation (PC-94 and PC-84); finally 
extrusion at 55°C was carried out for PC-74, PC-64 and PC-47. Separation of the liposomal 
suspension from unencapsulated PNA-a210 was achieved using a Sephadex G50 gel filtration 
column, pre-equilibrated with phosphate buffer. The amount of unloaded PNA eluted from the 
column was spectroscopically determined by UV-Vis measurements at λ=260 nm. The 
encapsulation efficiency (EE%, defined as the weight ratio of encapsulated PNA versus the 
amphiphilic molecules forming liposomes) and the encapsulation ratio (ER%, defined as the weight 
percentage of PNA encapsulated in the liposomes on the total PNA previously added during 
preparation) were quantified by subtraction of the amount of removed PNA from the total amount 
of loaded PNA. 
 
2.2 DSPE-PEG2000 post-insertion 
Dry DSPE-PEG2000 (an amount corresponding to the 6% mol of the final formulation) was 
hydrated for 2h with PNA containing liposomes at room temperature under stirring. 
 
2.3 DLS measurements and serum stability 
Mean diameters, diffusion coefficients (D), polydispersity indexes (P.I.) and Z potentials (ζ) of 
filled and empty liposomes were measured by Dynamic Light Scattering technique (DLS). DLS 
measurements were carried out using a Zetasizer Nano ZS (Malvern Instruments, Westborough, 
MA) that employs a 173° backscatter detector. Other instrumental settings are: measurement 
position (mm): 4.65; attenuator: 8; temperature: 25 °C; cell: disposable sizing cuvette. Size 
measurements were carried out on samples previously prepared, after centrifugation at room 
temperature at 13,000 rpm for 5 minutes at 2.0 ·10-4 M final lipids concentration. For each 
formulation, both hydrodynamic radii, polydispersity indexes and Z potentials were calculated as 
the mean of at least three measurements on three different batches. 
For the serum stability measurements, liposomes (5 mM) filled with PNA-a210, prepared as above 
described, were diluted at 2.5 mM with fetal bovine serum (FBS; Biowest, Nuaillé, France). The 
colloidal suspension was stirred at 37°C for 72 h. Samples withdrawn at different time points (30 
min, 1h, 2h, 4h, 8h, 16h, 24h, 28h, 36h, 48h and 72h) were diluted with bi-distilled water (1/50 v/v) 
and analyzed by dynamic light scattering according to the experimental setting described earlier. 
 
2.4 PNA-a210 liposomal release  
1.0 mL of PNA encapsulated liposomes was placed into a dialysis tubing (8-10 KDa MWCO) 
sealed at both ends with a knot. The dialysis bag was suspended in a release volume of 15 mL of 10 
mM phosphate buffer pH 7.4 and incubated with stirring at 37°C for 72 h. Before starting with the 
experiment, we checked that the crossing of the PNA molecules through the dialysis membrane 
occurred quickly, and that the overall release of PNA from the liposomes to the dialysis bag 
medium is the rate determining step process. Total PNA-a210 concentration in the dialysis tube was 
monitored versus time by collecting 2.0 mL aliquots at different time points from the release 
medium, and analyzing them via UV/Vis at 260 nm. The same volume of fresh buffer was added 
immediately to maintain a constant volume in the accepting solution. The extent of PNA-a210 
released was evaluated as percentage of the ratio between the amount of released PNA and of the 
total PNA previously loaded into the liposomes.  
 
3. Results and Discussion 
 
Several features of the commercial phospholipids, such as the length, the unsaturation degree of the 
alkyl portion and the charge of the head-group deeply influence lipid bilayer microfluidity, that is 
directly responsible for incorporation and retention of pharmaceutically relevant molecules 
(anticancer or anti-inflammatory drugs, nucleic acids, metal based contrast agents) (21-23). High 
rigidity of the bilayer corresponds to an improved retention of the encapsulated drug, while high 
microfluidity can lead to a reduction of the incorporation capability (23-25). Modulation of bilayer 
microfluidity can be also achieved through addition of cholesterol, extensively employed in 
liposomal formulations as stabilizing agent. On the basis of these observations, it appears clear that, 
when choosing the best formulation for the delivery of a drug, it is of capital importance to find the 
right compromise between fluidizing components, to maximize encapsulation, and rigidity 
conferring elements to improve stability and drug retention. Earlier studies reported by our group 
demonstrated the PNA oligomer PNA-a210 can be encapsulated in liposomes composed of 
PC/CHO/DSPE-PEG2000 (47/47/6 molar ratio) with an encapsulation efficiency of 1.69% and that 
the encapsulation efficiency was improved upon DSPE-PEG post-insertion (~ 30%, EE%: 2.20). 
This encapsulation protocol was chosen following results achieved by three different methods: thin 
film method/sonication, freeze/thawing , and SNALPs (18). Any substantial difference were 
observed in the encapsulation efficiency achieved by the three procedures. However, liposomes 
obtained with the freeze/thawing method showed lower polydispersity index with respect to the 
other preparations. In order to investigate the effect of the lipid bilayer fluidity on the incorporation 
and retention of PNA-a210, we compared the drug loading capability of liposomal formulations 
containing lipids with an alkyl chain of eighteen carbon atoms, characterized by different 
unsaturation degrees of the hydrophobic portion. The effect of the head group was evaluated by 
studying the encapsulation properties of liposomes prepared with lipids with DOPG. This 
phospholipid has the same hydrophobic portion of DOPC, but the neutral phosphatidylcholine head 
group is replaced by the negatively charged phosphatidylglycerol group. Furthermore, each 
phospholipid was used alone or in combination with an increasing percentage of cholesterol, 
ranging from 0 to 47%. Stealth liposomes were finally obtained by adding DSPE-PEG2000 (6 
mol%). In order to avoid the shielding effect of PEG during the PNA encapsulation, PEG surface 
decoration was achieved using the well-known post-insertion method.  
 
3.1 Preparation of the liposomes 
We investigated the effect of unsaturation of the lipids on the PNA encapsulation capability 
preparing liposomes composed of two-tailed phospholipids (HSPC, egg PC, DOPC, DOPG) and 
cholesterol at several molar ratios (10, 20, 30 and 47 mol (Table 1)). HSPC and DOPC contain zero 
and two unsaturations respectively (Fig. 1), while egg PC is composed of a mixture of natural 
phospholipids (average composition in fatty acids as follow: 32.7% of 16:0, 12.3% of 18:0, 32.0% 
of 18:1 and 17.1 % of 18:2), characterized by a highly variable unsaturation degree and 
hydrophobic chains at sixteen and eighteen carbon atoms. In order to exclude the influence of the 
encapsulation method on the loading efficiency and to reliably compare the encapsulation efficiency 
of each liposomal formulation, we applied an unique method for the preparation of all samples. This 
procedure is based on a combination of thin film/sonication and freeze/thawing methods (Fig. 2). In 
this new method we reduced the freeze/thawing cycles, because we observed a worsening of some 
liposomal preparations (in particular DOPG based liposomes) during the freeze/thawing. On the 
other hand, HSPC based liposomes did not give satisfactory results, in terms of PNA-a210 
encapsulation, when freeze/thawing step was not performed. However, due to the different melting 
temperatures (Tm) of the four phospholipids here studied, extrusion of the liposomes was performed 
at different temperatures (25°, 55° and 65°C). Tm, also defined as the gel to liquid-crystalline 
disordered phase transition, represents the temperature required to induce a change in the lipid 
physical state from the ordered gel phase, where the hydrocarbon chains are fully extended and 
closely packed, to the disordered liquid crystalline phase, where the hydrocarbon chains are 
randomly oriented and fluid. The phase transition temperature increases as a  function of 
hydrocarbon chain length, as a consequence of the high packing order favored by van der Waals 
interactions. The presence of one or more cis double bond into the acyl group destabilizes the 
interaction between the adjacent chains, thus requiring lower temperatures to prompt the transition 
from solid-gel to liquid-crystalline phase (26; 27). Moreover, the addition of cholesterol to a pure 
phospholipid bilayer causes a broadening of the Tm of the membrane. According to these 
considerations, the formulations containing DOPC and DOPG phospholipids, having a negative 
value of Tm, -20° and -18°C respectively, were extruded at room temperature, independently from 
the cholesterol content. All the liposomes containing HSPC were extruded at 65°C, well-above their 
transition temperature (Tm = 55°C of the pure phospholipid). Finally, PC based liposomes 
containing at 0 and 10% of cholesterol were extruded at room temperature, whereas the others three 
samples containing higher amounts of cholesterol (20, 30 and 47 mol%) were extruded at 55°C.  
 
3.2 Drug loading  
The amount of PNA encapsulated (expressed as μg), the encapsulation efficiency (EE%), defined as 
the weight ratio of encapsulated PNA versus the amphiphilic molecules forming liposomes, and the 
encapsulation ratio (ER%), defined as the weight percentage of PNA encapsulated in the liposomes 
on the total PNA previously added during preparation, are reported in Table 1. The encapsulated 
amount of PNA-a210 for each phospholipid is reported in Fig. 3 as a function of the cholesterol 
percentage. From the inspection of Fig. 3, it clearly appears that the four phospholipids here 
compared show pronounced difference in terms of encapsulation efficiency. A gradual increase in 
the encapsulation efficiency occurs at increasing the unsaturation of the alkyl chain, keeping fixed 
the choline head group (compare results obtained with pure liposomes of HSPC, egg PC and 
DOPC). Accordingly ER% moves from 38.2 for pure HSPC liposomes to 62.6 for pure DOPC 
liposomes. Egg PC and DOPC showed a similar behavior (ER% 64.5 and 62.6, respectively), being 
egg PC a mixture of natural phospholipids with a variable unsaturation degree and chain length. On 
the other hand, a clear increase in the encapsulated amount (ER% 87.8) was observed for pure 
DOPG liposomes, as compared to the other formulations. These results indicate that the 
combination of two unsaturations on the alkyl chain with a negatively charged head group causes a 
substantial increase in the PNA loading degree. The effect of addition of cholesterol on PNA 
loading efficiency was evaluated for all the phospholipids selected for this study, using amounts of 
cholesterol ranging from 10 to 47 mol%. It is well-known that the insertion of cholesterol can cause 
an opposite effect on the lipid bilayer fluidity depending on the Tm value of the neighboring 
phospholipids (28). Above the Tm, the interaction of rigid cholesterol molecules with hydrocarbon 
tails of phospholipids causes a stiffening of the lipid bilayer, which becomes less permeable to 
small water-soluble molecules. On the contrary, a weakening of interactions between the alkyl 
chains of phospholipids occurs when cholesterol is added at bilayers in their gel state (temperature 
below the Tm). According to these findings, the addition of low amounts (10 and 20 mol%) of 
cholesterol in liposomes composed of the completely saturated HSPC phospholipid, which exhibits 
a Tm of 55°C, arouses a weakening of the lipid bilayer. The higher mobility of the bilayer causes an 
increase of the encapsulation efficiency (ER% increase from 38 to 48%), as indicated in Fig. 3 and 
in Table 1. However, the addition of higher percentages of cholesterol (30 and 47 mol%) does not 
result in a further increase of the loading capability. On the other hand, the loading capability of 
liposomes containing DOPC and DOPG, both with two unsaturations and having very low Tm 
values, decreases proportionally with increasing the cholesterol content. This trend is more 
pronounced for DOPC liposomes than for DOPG ones: a decrease of 42% and 21% of the 
encapsulation ratio was observed for DOPC-47 and DOPG-47, respectively. This different trend 
beyond validates the hypothesis that also the head group of the phospholipid contributes at 
modifying the loading capability of liposomes. Due to the high complexity of natural egg PC 
composition, it is not easy to focus and describe the influence of the cholesterol on its loading 
properties.  
 
3.3 Structural characterization 
After preparation, mean diameters, polydispersity indexes (P.I.) and Z potentials (ζ) of empty 
liposomes and PNA loaded liposomes, before and after post-insertion of DSPE-PEG2000, were 
assessed using Dynamic Light Scattering (DLS) technique (see Table 2, S1, S2 and S3). The size of 
all the empty liposomes is in good agreement with the literature and is not significantly affected by 
the cholesterol percentage used in the formulation (Table 2). All the formulations showed a slight 
reduction of the liposomal dimensions after the loading of PNA-a210, independently from the 
cholesterol percentage. The variation of the mean diameter of PNA loaded liposomes as a function 
of the cholesterol percentage before and after post-insertion of DSPE-PEG2000, is reported in Fig. 
4. After post insertion of the DSPE-PEG2000, DLS intensity profiles of DOPC and DOPG show a 
moderate increase of the mean diameter ranging between 5 and 10% of the size before post-
insertion. On the contrary, the post-insertion of DSPE-PEG2000 in egg PC based liposomes causes 
a decrease of the liposome size. This decrease probably depends from the insertion of a 
phospholipid with two saturated C-18 chains in a bilayer of saturated and unsaturated lipids at C-16 
and C-18 chains, which produces a condensing and ordering effect on the acyl chains, resulting in 
the contraction of the liposomal size. Z potential values of all the PNA filled liposomes are also 
reported in Tables 2, S1, S2 and S3. Both liposomes containing phosphatidylcholine and 
phosphatidylglycerol as head groups are negatively charged. As expected, liposomes formulated 
using the negative DOPG lipid have a more negative ζ value (- 48 < ζ < - 61 mV). Z potential for 
PNA-a210 in water solution was also measured in order to evaluate the occurrence of electrostatic 
interactions between the negative liposomal surface and PNA-a210. ζ value of PNA was found 
close to zero (data not shown), thus suggesting that any electrostatic interaction occurs. After 
DSPE-PEG2000 post-insertion, all the liposomes have ζ values ranging from - 18 to - 33 mV, thus 
indicating that polyethylene glycol shields the charge of the phospholipids.  
Stability of PNA loaded liposomes was evaluated in vitro in fetal bovine serum. Liposomes were 
incubated with serum and the evolution of their dimensions was checked by DLS measurements at 
different time points up to 72 h. It is well-known that both liposome composition and charge can 
affect the stability of liposomes in serum (29). Negatively charged liposomes containing only one 
phospholipid show low stability in serum; the insertion of cholesterol results in the improvement of 
liposome stabilitydue to membrane modification and consequent inhibition of the interactions 
between liposomes and serum proteins. Liposomes here prepared do not show signification 
variations of their size upon the time (data not shown), thus indicating a good stability. A similar 
result was previously observed by us with liposomes composed of egg PC/Chol/DSPE-PEG2000 at 
47/47/6 molar ratio (18) In our opinion this result can be explained on the basis of the similitude 
between the external surface of the liposomes here prepared with the post-insertion of DSPE-
PEG2000.  
 
3.4 PNA-a210 release 
On the basis of the drug loading data, only DOPG based liposomes were selected to be further 
investigated for the release of PNA from liposomes. The release profile of PNA-a210 from DOPG 
based liposomes prepared at different amounts of cholesterol (0, 10, 20, 30 and 47 mol%) was 
studied within 72 h, using a dialysis membrane immersed in phosphate buffer at 37°C. As expected, 
the percentage of PNA released from the liposomes is strongly influenced by the amount of 
cholesterol of each formulation (Fig. 5). From the comparison of the profiles reported in Fig. 5, the 
highest release percentage (55%) was observed for the liposomal formulation which lacks 
cholesterol. The addition of a low (10%) amount of cholesterol causes a better retention of the PNA 
in the inner liposomal compartment and a decrease of release percentage (~ 34%). This effect is 
more evident at 20 mol% (~ 27%), whereas the further increase of cholesterol does not produce 
significant variations. On the contrary, a decrease of the release was observed when the cholesterol 
percentage is brought at 47 mol%. This behavior is expected for the release of hydrophilic 
molecules encapsulated in liposomal formulations containing cholesterol quantity above 40% (30). 
In accordance with drug release results, the best percentage of cholesterol to use should be ranged 
between 20 and 30 %.  
 
4. Conclusions 
 
PNA loading capability of liposomes composed of saturated (HSPC) and unsaturated (Egg PC, 
DOPC and DOPG) commercial phospholipids was evaluated in terms of encapsulation efficiency 
and of encapsulation ratio. The effect of increasing amounts of cholesterol in the liposomal 
composition was also investigated. Results indicate that the PNA loading is strongly affected by 
both unsaturation of the lipid alkyl chains and by the charge of the head group. A gradual increase 
in the encapsulation efficiency occurs at increasing the unsaturation of the alkyl chain, keeping 
fixed the choline head group. The replacement of choline head group with the negatively charged 
glycerol causes a further increase in the PNA loading degree. The insertion of low amount of 
cholesterol (10-20%) in DOPG based liposomes provides a slight decrease of the PNA loading. 
In addition, an amount of cholesterol ranging between 20 and 30% causes a slowing down of the 
PNA’s release from the liposomal formulation. For their encapsulation and the release properties, 
we can conclude that PEGylated DOPG liposomes with a percentage of cholesterol of 10-20% can 
be considered the best formulation for the loading of PNA-a210. Future investigations will be 
carried out to understand whether the composition of the PNA oligomers (i.e. the purine:pyrimidine 
ratio) affects the loading capability of DOPG based liposomes. 
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Figures  
 
 
 
Fig.1. Schematic representation of phospholipids used for the liposomal formulations: HSPC, egg 
PC, DOPC, DOPG and DSPE-PEG2000. For egg PC, which is a mixture of natural phospholipids, 
is here only represented the predominant fatty acid. 
 
  
 Fig.2. Preparation of PNA loaded liposomes in three steps: 1) the mixture of lipids was dried under 
vacuum to form a lipid film on the wall of the vial, then the film was hydrated and sonicated with 
the buffer; 2) PNA solution is added to the vial and liposomes undergone to five freeze/thawing 
cycles; 3) liposomes were made stealth by adding DSPE-PEG2000 using the post-insertion method.  
 
  
  
Fig.3. Amount of PNA-a210 (μg) encapsulated in 10 mM liposomes composed of HSPC, egg PC, 
DOPC or DOPG and cholesterol at different percentages. μg of PNA-a210 encapsulated in 
liposomes are reported as the mean of the three experiments.  
 
  
 Fig.4. Mean diameter of all the PNA loaded liposomes as a function of the cholesterol content 
(mol%) before (Lipo) and after post-insertion (PEGylated-Lipo) of DSPE-PEG2000. Diameter 
values are reported with the error bars as the mean of the three experiments.  
 
  
  
 
Fig.5. Release of PNA-a210 by DOPG based liposomes prepared at different percentages of 
cholesterol (0, 10, 20, 30 and 47 mol%). The amount of PNA-a210 released (%) was estimated by 
UV-Vis at 260 nm and reported with the error bars as function of the time in hours. 
 
  
 Table 1: Liposomal formulations and μg of PNA-a210 encapsulated in 1 mL of liposomes at 10 
mM lipid concentration. EE% and ER% for each sample are also reported. 
 Sample Cholesterol  
amount (mol) 
PNA (µg) enc ER% EE% 
H
S
P
C
 
HSPC-94 ----- 76.5 38.2 1.67 
HSPC-84 10 95.5 47.8 2.34 
HSPC-74 20 94.2 47.1 2.45 
HSPC-64 30 88.1 44.1 2.43 
HSPC-47 47 82.5 41.1 2.53 
 
P
C
 
PC-94 ----- 128.9 64.5 2.79 
PC-84 10 123.2 61.6 2.98 
PC-74 20 134.9 67.5 3.49 
PC-64 30 130.1 65.0 3.55 
PC-47 47 107.0 53.5 3.27 
 
D
O
P
C
 
DOPC-94 ----- 128.3 62.6 2.72 
DOPC-84 10 110.8 54.0 2.64 
DOPC-74 20 101.7 49.6 2.57 
DOPC-64 30 99.52 48.5 2.69 
DOPC-47 47 74.33 36.3 2.23 
 
D
O
P
G
 
DOPG-94 ----- 177.0 87.8 3.66 
DOPG-84 10 165.1 82.6 3.88 
DOPG-74 20 161.2 80.6 4.03 
DOPG-64 30 152.9 76.4 4.07 
DOPG-47 47 138.8 69.4 4.14 
 
 
 
 
 
 Table 2: Structural parameters (mean diameter, P.I., D, ζ) from DLS measurements for DOPG 
based liposomes empty or encapsulating PNA-a210, before and after DSPE-PEG2000 post-
insertion. Standard deviation (SD) for values of diameter, diffusion coefficient and Z potential are 
also reported.  
Sample 
Mean diameter ± SD 
(nm) 
P.I. D [m
2
 s
-1
]x10
-12
 
ζ mV ± SD 
 Empty PNA Empty PNA Empty PNA Empty PNA 
DOPG-94 118 ± 46 106 ± 44 0.107 0.112 4.2 ± 1.6 4.7 ± 1.9 -27.3  ± 1.7 -51.3 ± 1.7 
PEGylated 
DOPG-94 
124 ± 54 110 ± 41 0.122 0.102 4.0 ± 1.7 4.5 ± 1.7 -18.2  ± 0.5 -27.7  ± 3.1 
DOPG-84 112 ± 44 111 ± 56 0.093 0.155 4.4 ± 1.7 4.4 ± 2.2 -26.6  ± 3.4 -61.0  ± 1.1 
PEGylated 
DOPG-84 
116 ± 40 117 ± 68 0.086 0.193 4.3 ± 1.5 4.2 ± 2.4 -18.7  ± 0.4 -31.3  ± 0.7 
DOPG-74 116 ± 37 114 ± 50 0.072 0.136 4.3 ± 1.4 4.3 ± 1.9 -37.2  ± 2.3 -58.7  ±2.1 
PEGylated 
DOPG-74 
121 ± 34 119 ± 51 0.042 0.132 4.1 ± 1.1 4.1 ± 1.8 -24.5  ± 1.5 -33.3  ±1.5 
DOPG-64 117 ± 41 104 ± 53 0.079 0.165 4.2 ± 1.5 4.7 ± 2.4 -37.8 ± 1.9 -54.7  ± 1.4 
PEGylated 
DOPG-64 
118 ± 46 108 ± 50 0.091 0.134 4.2 ± 1.6 4.6 ± 2.1 -33.0 ± 0.9 -32.2  ± 0.5 
DOPG-47 112 ± 42 103 ± 57 0.092 0.202 4.4 ± 1.6 4.8 ± 2.6 -31.0 ± 0.3 -48.6  ± 1.1 
PEGylated 
DOPG-47 
115 ± 45 109 ± 55 0.106 0.154 4.3 ± 1.7  4.5 ± 2.3 -35.0 ± 3.3 -31.3  ± 0.3 
 
 
 
 
 
 
 
 
 
 
